New research indicates that people who come off popular GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who stop traditional lifestyle programs.
Research printed in a leading medical journal shows that while overweight people can lose a large proportion of their body weight while undergoing treatment, the mass returns at an estimated rate of nearly a kilo each month after stopping.
"People buying such treatments need to be cognizant of the risk of rapid rebound weight gain when the therapy concludes," warns expert Dr. Susan Jebb.
This pace of regain implies a reversion to pre-treatment weight in about 18 months.
Weighing Treatments
The research, which reviewed 37 of trials involving thousands of patients, compared the results of these new drugs with conventional dieting.
The team note that individuals who lose weight through dieting typically see a more gradual creep back—perhaps 0.1 kg a month—post-intervention.
Understanding the Quick Rebound
Doctors believe the way of the drugs is key to understanding the heightened regain.
The injections mimic a body's own chemical called GLP-1, which helps regulate feelings of fullness.
"Artificially providing the hormone levels several times higher than the body's typical production could lead to the body to generate a reduced amount of its own natural hormone, and may also diminish sensitivity to its actions," said Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this GLP-1 'fix' means hunger is no longer kept in check, making excessive eating far more likely."
An Ongoing Issue?
The NHS advise the injections for individuals with obesity-related health risks, alongside recommended diet and exercise modifications.
Professionals contend that, due to the likelihood of relapse, the treatment is often life-long.
This opinion is supported by pharmaceutical companies, who note that the results "highlight the long-term character of excess weight," comparing it to managing diseases like hypertension.
User Accounts
Users who have come off the jabs describe a intense resurgence of hunger.
"It was like a trigger activating and I was suddenly starving," described a patient.
This challenge is compounded if individuals have not developed sustainable dietary or behavioural changes during therapy.
Significant Adoption
Figures suggest that a significant number of people in the UK have tried these injections in the last 12 months, with desire continuing to grow.
- Use is more common among females than men.
- The 40s and 50s demographic shows the greatest level of interest.
- Many access the drugs through private prescriptions rather than public health services.
Ultimately, clinicians stress that while these medications are effective agents for shedding pounds, they are not a standalone fix and maintained weight loss likely depends on ongoing lifestyle management.
